Category: Kidney disease

The U.S. Food and Drug Administration (FDA) first approved generic versions of cinacalcet on March 8, 2018. This milestone introduced competition for the brand-name drug Sensipar, which had sales of $1.72 billion in 2017. The question of *when did cinacalcet go generic?* is pivotal for understanding patient access and cost.

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), with a global prevalence estimated at 49.5%. To manage this and related conditions, a key question for patients and providers is, **what is Cinacalcet?** It's a vital medication for controlling hormone levels.